FDA approval of REZDIFFRA (resmetirom) for NASH/MASH treatment

Поделиться
HTML-код
  • Опубликовано: 19 окт 2024

Комментарии • 7

  • @usernamehere94
    @usernamehere94 6 месяцев назад +2

    Thank you very much for making this video. You're one of the only channels that (I'm aware of) covers medicinal chemistry in an accent that I can understand easily. Please keep up the great work as long as you are able.

    • @ChemHelpASAP
      @ChemHelpASAP  6 месяцев назад

      I'm working on it. Sometimes it's hard to keep up with the FDA.

  • @joshyu1124
    @joshyu1124 6 месяцев назад +1

    resmetirom also has liver-loading property, about 8:1 liver to plasma ratio in mice. Great video!

    • @ChemHelpASAP
      @ChemHelpASAP  6 месяцев назад

      In this case, the idea that an oral drug must first traverse the liver, which happens to be its site of action, can be leveraged to some benefit.

  • @rahulmalik4887
    @rahulmalik4887 5 месяцев назад

    Is it use in alcohal hepatitis

  • @mihirpal8561
    @mihirpal8561 3 месяца назад +1

    Is resmetirom for NAFLD or for NASH or for both?

    • @ChemHelpASAP
      @ChemHelpASAP  3 месяца назад

      Resmetirom is approved for NASH, not NAFLD. It might help on NAFLD, but the drug's efficacy was measured on steatohepatitis.